George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
PL75, you are probably right, and the RNS statement ref the option of repaying in cash is “pandering to the twatterati”. But I still hope the company occasionally use it as disruptor strategy to counteract the shorters. TW etc have had a field day at our expense.
Evening Earl, my thoughts are that they are trying to appease investors, the majority (especially LTH’s) who are in the red. I appreciate that the placing was to fund AVA6000 and the preclinical pipeline, but if it wrong foots the shorters and helps put a floor under the SP, then I hope they do it.
Here is one of mine.
The company has said (RNS 22/4) “if it considers that conditions allow, the repayment [to Heights] will be settled in cash.” To avoid dilution will the company consider paying the next instalment in cash if the share price remains at these low levels?
Dibs, the contract value may not be large but I think you are missing the point when you call it “derisory”. The importance of the contract is that it is a foot in the door of a major pharmaceutical company.
AS himself, in today’s interview, acknowledged that £150,000 is a small amount of money, but it has a “massive flow through potential”. AGL will aim to build on this new relationship with AstraZeneca. AN also referred to
“the halo effect of working with AstraZeneca” and that “they are a critical reference customer for the rest of our business.” It is a huge endorsement of AGL and Parsortix to be used by a company of the stature of AstraZeneca, who are a genuine household name.
Another positive is that the DDR assay developed and paid for by Artios is being used and developed further for AstraZeneca’s requirements. So, not only have AGL been paid to develop the Artois assay, but it can then be offered to other customers.
I think it’s a great result from the AGL team.
Alcibiades,
I don’t follow all the aspects of your post. For example, we are still awaiting details/TR1’s for the II who have “gobbled up” PI’s holdings.
Does “emissions” mean shares? How do we know they “went mainly to the largest IIs on board already” ?
And the convertible bond was issued to Conifer? Do you mean Heights Capital?
BSHL2, I think you may have misinterpreted Wyn’s post, which referred to Myles? I’m pretty certain that Wyn wasn’t referring to Bellamy, when he posted “There was a time the release of his latest update even moved the SP.....”
I disagree GeneralOz, I don’t feel as though there is a dark cloud over this company. The manner of the raise may have temporarily dented sentiment but the cash they now have strengthens their negotiating position. Short term pain unfortunately for LTH’s, but hopefully mid-long term gain.
I’m guessing, LDA, that AS will address some questions re the placing etc at the prelims. Better to answer some of them now rather than have them “stored” up for a stormy AGM. Can he, for example, give us some detail on who the high quality institutional investors/large European healthcare specialist are?
Morning BV, I found a copy of the TG notes, and yes, it was Fiona who answered a question about weekly dosing:
“Now that we have seen how safe AVA6000 is we know we could do more frequent dosing. It’s important to remember we are not dosing Dox but AVA6000 which is a targeted version of DOX and dosing every two weeks may give better outcomes for patients. Weekly dosing could increase toxicity and fatigue, so it may be considered in the future but we have decided to trial fortnightly dosing.” (18th October 2023)
https://x.com/sarahjean191/status/1717536397416869977?s=61&t=yGNoQ6Xj0Lw6rjPJMTuiZA
( I am not Sarah Stevens, I just remember her posting the notes)
BSHS2L, this is a clinical trial with clearly defined parameters agreed by the Safety Data Monitoring Committee. I think it unlikely that a patient could move from one dosing regimen to another, especially as the fortnightly trial is in its very early stages? But that is supposition on my part and not fact.
Interesting suggestion, but I am surmising it is probably not possible?
TG2D, you are talking cr*p. Angle, itself, is using Parsortix for studies in ovarian & prostate cancer and plan to offer LDT’s for them. Two of AGL’s customer’s are using Parsortix in non MBC trials. There are countless independent studies using Parsortix for a whole host of different cancer types. AN has explained, on a number of occasions, how CLIA accredited labs can use Parsortix for different cancers. And yet, you still persist talking rubbish.
If your motive is to annoy people, well congratulations it’s working with me. I don’t like filtering people, because I like to hear different views, but I am going to make an exception with you. You’re binned.
I will be paying more attention than usual to the Diagnostic division in the upcoming prelims. In the TP note it said “Avacta’s Board expects the Diagnostics division to become EBITDA positive in 2H 2024 and cash generative in 2025.”
Shareholders don’t want it indefinitely losing money and the for sale sign is up, so we obviously want the best return when it’s flogged. It’s going to be very interesting to see what DX eventually sells/is divested for.
Agreed PL, has the DX side contributed/developed anything marketable since the LFT’s?
I invested because of the potential of the Therapeutics division and have never had much interest in the Diagnostics. I re-listened to what AS said in the interims about it, it wasn’t very compelling, and is even less so now.
Hi Noix again. I wasn’t invested at the time of the last presentation and watched it “retrospectively”. From memory, I think there were about four questions asked. If there were others that were not later addressed, then that is poor.
Morning Noix, it was the same with last year’s results - the Investor Meet presentation was with both the CEO & CFO.
To the people who routinely report/censor posts, please will you take into consideration that LSE will also wipe out a whole load of other post as well. It makes trying to catch up on the day’s posts very disjointed and interesting posts get deleted. There is also not much point in taking time to write a post if it’s just going to be indiscriminately removed.
There has been criticism of the Telegram group but this board is more controlling of content. Much better to use the poster filter on here rather than having a whole “conversation” deleted.
Thanks CTSFO for posting the TD research note.
https://www.trinitydelta.org/research-notes/aacr-data-continue-to-support-confidence-in-ava6000/
Wyn, I disagree with your comment: “I also think that if the data was as compelling as we all have been told, getting patients for the trial would have taken, oh, |I don't know about 5 minutes?” The “5 minutes” patient enrollment reference may have been meant flippantly but it disrespectful to the patient’s who are very ill, and to quote Andrew Saunders are “very much doing an altruistic act in entering these trials…..”.
AS’s missed timelines may be frustrating if they are unrealistic, but these are people’s lives we are talking about, the screening process cannot be compromised for the sake of shareholders. The company and the oncologists also need to be selective in their choice of patients in order to get the optimum results for the trial.
The trouble with the self appointed censors of the board getting posts deleted is that other posts also get swept up.
So I will repost mine to Touk.
The word “exceeded” is used twice by AS in the PH VOX interview 13th December 2023.
“I think it's fair to say that what we have now has EXCEEDED all expectations and that the overarching takeaway message from the data we released this morning is that Pre|CISION is doing exactly what it was intended to ……….we're in a position where we can see now that we can improve the quality of life of patients and that was probably, pragmatically our aim when we started the safety study. But as I say, we've far EXCEEDED that now…..”
The first mention is approximately 3:13 into the interview.
https://www.voxmarkets.co.uk/articles/q-a-with-avacta-s-ceo-alastair-smith-790c4e8/